Publication: Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients
Loading...
Date
2018
Journal Title
Journal ISSN
Volume Title
Publisher
John Wiley & Sons, Ltd.
Abstract
Background: Revascularisation is the gold standard therapy for patients with critical limb ischaemia (CLI). In over 30% of patients who are not suitable for or have failed previous revascularisation therapy (the 'no-option' CLI patients), limb amputation is eventually unavoidable. Preliminary studies have reported encouraging outcomes with autologous cell-based therapy for the treatment of CLI in these 'no-option' patients. However, studies comparing the angiogenic potency and clinical e'ects of autologous cells derived from di'erent sources have yielded limited data. Data regarding cell doses and routes of administration are also limited.
Objectives: To compare the e'icacy and safety of autologous cells derived from di'erent sources, prepared using di'erent protocols, administered at di'erent doses, and delivered via di'erent routes for the treatment of 'no-option' CLI patients.
Search methods: The Cochrane Vascular Information Specialist (CIS) searched the Cochrane Vascular Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINEOvid, EmbaseOvid,the Cumulative Index toNursing and AlliedHealth Literature (CINAHL),the Allied and Complementary Medicine Database (AMED), and trials registries (16 May 2018). Review authors searched PubMed until February 2017.
Selection criteria: We included randomised controlled trials (RCTs) involving 'no-option' CLI patients comparing a particular source orregimen of autologous cell-based therapy against another source or regimen of autologous cell-based therapy.
Data collection and analysis: Three review authors independently assessed the eligibility and methodological quality ofthe trials.We extracted outcome data from each trial and pooled them for meta-analysis. We calculated e'ect estimates using a risk ratio (RR) with 95% confidence interval (CI), or a mean di'erence (MD) with 95% CI.